SCHEMBL23327907

SCHEMBL23327907

O=C(NCc1cccnc1N1CCOCC1)c1cnnc(-c2ccc(Cl)nc2)c1

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 8/20 0.66
SCN2A Q99250 6/20 0.66
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM1A O60341 3/20 0.42
HDAC1 Q13547 3/20 0.42
MAPT P10636 1/20 0.42
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
P2RX7 Q99572 1/20 0.40
MCHR1 Q99705 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23327910 0.92 SCN10A (0.75) SCN10ASCN2AKDM1AHDAC1MCHR1
SCHEMBL23327655 0.89 SCN10A (0.68) SCN10ASCN2AKDM1AHDAC1P2RX7
SCHEMBL23344751 0.89 SCN10A (0.62) SCN10ASCN2AKDM4EKDM1AHDAC1
SCHEMBL30882123 0.88 SCN10A (0.68) SCN10ASCN2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL23328017 0.88 SCN10A (0.68) SCN10ASCN2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL23344685 0.86 SCN10A (0.60) SCN10ASCN2AKDM1AHDAC1GAA
SCHEMBL23327999 0.86 SCN10A (0.61) SCN10ASCN2AKDM1AHDAC1
SCHEMBL23328023 0.85 SCN10A (0.56) SCN10ASCN2AKDM1AHDAC1MCHR1
SCHEMBL23328010 0.84 SCN10A (0.57) SCN10ASCN2AKDM1AHDAC1MCHR1
SCHEMBL23327995 0.84 SCN10A (0.71) SCN10ASCN2AKDM1AHDAC1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 EP claimed
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 LIEBER INSTITUE, INC (US) 2024-05-28 US claimed
CN-112689629-B For inhibiting Nav1.8 Pyridazine Compounds 利伯研究所公司 2024-04-23 CN claimed
EP-3820860-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 Lieber Institute, Inc. (US) 2021-05-19 EP claimed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US claimed
CN-112689629-A For inhibiting Nav1.8 pyridazine Compounds 利伯研究所公司 2021-04-20 CN claimed
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 EP disclosed
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 LIEBER INSTITUE, INC (US) 2024-05-28 US disclosed
CN-112689629-B For inhibiting Nav1.8 Pyridazine Compounds 利伯研究所公司 2024-04-23 CN disclosed
EP-3820860-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 Lieber Institute, Inc. (US) 2021-05-19 EP disclosed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US disclosed
CN-112689629-A For inhibiting Nav1.8 pyridazine Compounds 利伯研究所公司 2021-04-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN5A, SCN2A SCN10A 8/4885SCN2A 3/4885KDM4E 3022/4885
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 SCN8A, SCN5A, SCN2A SCN10A 8/4885SCN2A 3/4885KDM4E 3022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.